Physician profile
James Edwin Bolander
NPI 1639176464
$1,122.93
in general payments reported to CMS, 2019-2025
13 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.65 · 2022: $161 · 2023: $121 · 2024: $356 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.01 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $370.11 | 2023-2025 | |
| Amgen INC. | $227.31 | 2024-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $141.57 | 2022 | |
| Calliditas Therapeutics US INC. | $82.93 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $68.29 | 2021-2025 | |
| Ardelyx, INC. | $62.84 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.32 | 2023-2024 | Jardiance |
| Nxstage Medical, INC. | $39.25 | 2025 | Liberty Select Cycler, Nxstage System One |
| Aurinia Pharma U.S., INC. | $35.08 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $23.99 | 2025 | Jynarque |
| Horizon Therapeutics Plc | $13.63 | 2023 | Krystexxa |
| Novo Nordisk INC | $13.53 | 2024 | Wegovy |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bolander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.